Compare Consolidated Edison, Inc. (ED) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Smith & Nephew plc — how do they compare? Consolidated Edison, Inc. trades at $106.14 (market cap $39.20B), while Smith & Nephew plc trades at $27.2 (market cap $11.10B). The key difference: Consolidated Edison, Inc. is far larger — about 3.5× Smith & Nephew plc's market cap, and Consolidated Edison, Inc. pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Smith & Nephew plc for 120 Days on average.
| ED | SNN | |
|---|---|---|
Market Cap | $39.20B | $11.10B |
Volume | 2,142,900 | 1,051,703 |
Sector | Utilities | Health |
52-Week High | $115.46 | $37.17 |
52-Week Low | $95.37 | $26.42 |
Typical Hold Time | 75 Days | 120 Days |
Enterprise Value | $66.05B | $14.13B |
Dividend Yield | 3.31% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $104.65, down 0.45% on the day, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The company maintains solid fundamentals with a P/E of 17.43, net income margin of 12.53%, and a $0.89 dividend. Revenue grew to $16.92B in 2025, with cash flow from operations strong at $4.80B. Analyst consensus is a Hold with a $106.33 price target, slightly above the current price.
ED's outlook is stable, supported by its utility business model and dividend aristocrat status, but faces risks from high debt levels and interest expenses. The stock offers income appeal with moderate growth potential, though investor sentiment is cautious amid mixed analyst ratings and institutional selling trends noted in recent filings.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
